Standalone Q2 FY27 revenue up 652%; profit after tax up 573% vs Q2 FY26
SHUKRAPHAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Standalone Q2 FY27, ended 30 September 2026: revenue rose 652% to Rs 44.20 crore from Rs 5.88 crore, while profit after tax rose 573% to Rs 16.01 crore from Rs 2.38 crore a year earlier. EBITDA was Rs 22.01 crore with a 49.8% margin, versus negative Rs 0.42 crore and negative 7.1%. Standalone H1 FY27 revenue was Rs 67.73 crore and profit after tax Rs 31.04 crore. Exports drove growth, but inventory and longer payment cycles were trade-offs.
Strong growth and margin gains may support sentiment, but export dependence, higher inventory and longer payment cycles raise execution risks.
The company's XBRL figures for this quarter look filed in the wrong unit: revenue reads ₹44.20 Cr against ₹5.88 Cr a year ago, about 8× larger. A move that size is almost always a wrong unit, not a business, so nothing is computed from these figures and no number-based tags are set; the read above is the AI's, from the document.